AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CUE · NASDAQ · Biotechnology

Cue Biopharma

Develops immune-modulating biologics for autoimmune and allergic diseases.

$27.88

After-hours close−0.30 (−1.06%)

At close$28.18(+0.07%)

Something off on this page? Send us feedback.

Profile

Cue Biopharma, Inc.CUEHealth Care

Develops injectable biologics that selectively modulate disease-specific T cells in vivo. Active programs pair the Immuno-STAT-derived CUE-401 autoimmune candidate with CUE-221, a Phase 2 anti-IgE antibody for allergic diseases licensed outside Greater China.

Develops injectable biologics intended to selectively modulate disease-specific T cells in vivo. Its Immuno-STAT platform underpins CUE-401, which combines engineered IL-2 and TGF-beta signals and is advancing toward Phase 1 for autoimmune and inflammatory disease.

The active pipeline also includes CUE-221, a Phase 2 anti-IgE antibody for allergic diseases, licensed for global rights outside mainland China, Hong Kong, Macau, and Taiwan. Earlier molecules have been licensed to Boehringer Ingelheim and ImmunoScape.

Commercialization depends on further research, clinical testing, potential regulatory approval, and execution under the CUE-221 license and partner arrangements.

Company facts

CEOShao-Lee Lin, M.D., Ph.D.

ListedJan 2, 2018

ExchangeNASDAQ

HeadquartersBoston, MA

CountryUnited States

Employees29

CIK0001645460

ISINUS22978P2056

Key statistics

Market cap$73.3M

EPS (ttm)−$27.00

P/E (ttm)−1.03

ROE-1,032.2%

P/B76.53

P/S1.95

Dividend yield—

Beta2.94vs XLV −0.75

Year to date +178% · Average volume (30d) 195.5K

Analysts

Price target, next 12 months$4.00−85.7%Median of 9 analysts · vs the Aug 28 close

ConsensusBuy9 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $27.88

High$7.00−74.9%

Median$4.00−85.7%

Low$2.00−92.8%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$1.35

ReportedDue Nov 12, 2026

Revenue

Estimate$1.6M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 14, 2026Q2 FY26	−$1.69	−$24.14	−1,328.4%	$3.0M	$7.9M	+162.6%	−19.18%
May 14, 2026Q1 FY26	−$3.30	−$1.08	+67.3%	$2.5M	$5.7M	+127.4%	−9.16%
Mar 16, 2026Q4 FY25	−$2.70	$0.30	+111.1%	$1.0M	$21.9M	+2,094.2%	−12.83%
Nov 12, 2025Q3 FY25	−$0.10	−$0.07	+30.0%	$2.3M	$2.1M	−6.1%	−7.19%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$421.0K	$3.0M	$2.1M	$21.9M	$5.7M	$7.9M
Gross profit	$421.0K	$3.0M	$2.1M	$21.9M	$5.7M	$7.8M
Operating income	−$12.3M	−$8.6M	−$7.5M	$2.0M	−$5.4M	−$87.7M
Net income	−$12.3M	−$8.5M	−$7.4M	$1.6M	−$5.2M	−$153.1M
Diluted EPS	−$5.10	−$2.66	−$2.21	$0.43	−$1.08	−$24.14
Gross margin	100.0%	100.0%	96.3%	100.0%	100.0%	99.5%
Operating margin	-2,921.4%	-292.3%	-351.0%	8.9%	-94.3%	-1,113.3%

Fiscal years (4-quarter sums)FY21 $14.9M · FY22 $1.2M · FY23 $5.5M · FY24 $9.3M · FY25 $27.5M

Balance sheet, Jun 30, 2026Cash & short-term investments $17.4M · Total debt $8.8M · Total assets $30.7M · Shareholders' equity $2.3M

Dividends

No dividends on record.

Ownership

Institutions 62.46%1.64M sharesInsiders 25.86%679.5K sharesOther 11.68%306.9K shares

Shares outstanding 2.63M · Float —

Float — provider float is below the insider stake.

A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.

A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.

The provider's float is smaller than the insider stake it should exclude, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Shao-Lee Lin	467.2K	6.20%	13D	Aug 21, 2026
Shao-Lee Lin · director, officer: Chief Executive Officer	467.2K	17.78%	Form 4	Aug 14, 2026
Bleichroeder LP	370.7K	14.11%	13F	Aug 13, 2026
Driehaus Capital Management LLC	292.1K	6.96%	13G	Aug 14, 2026
Vanguard Capital Management LLC	161.7K	6.15%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 13, 2026	Michael Vincent Meluzio	officer: VP, Prin. Accounting Officer	−5,628	$30.09
Aug 13, 2026	Sumita Ray	officer, other: Chief Legal Compliance Officer	−8,829	$30.09
Aug 13, 2026	Shao-Lee Lin	director, officer: Chief Executive Officer	−18,258	$28.62
Aug 12, 2026	Shao-Lee Lin	director, officer: Chief Executive Officer	−40,000	$27.10
Jun 1, 2026	Shao-Lee Lin	director, officer: Chief Executive Officer	+136,359	$3.67